Skip to main content
. 2013 Aug;98(8):1259–1263. doi: 10.3324/haematol.2012.080929

Figure 2.

Figure 2.

Tumor burden correlates inversely with rituximab serum concentration and half-life. (A) Median serum rituximab half-life in the first treatment cycle for patients with high (n=8) and low (n=9) tumor burden (P=0.02 by Student’s t-test). (B) ALC (solid lines) and rituximab trough levels (dotted lines) over time in 2 representative patients.